Abstract
Restless Legs Syndrome (RLS) is a sensorimotor disorder that severely affects sleep. It is characterized by an urge to move the legs that is often accompanied by periodic limb movements during sleep (PLMS). RLS has a high prevalence in the population and is usually a life-long condition. While its origins remain unclear, RLS is initially highly responsive to treatment with dopaminergics that target the D3 receptor. However, over time patients often develop a gradual tolerance that can lead to the emergence of adverse effects and the augmentation of the symptoms. While the basal ganglia and the striatum control leg movements, the lumbar spinal cord is the gateway for the sensory processing of the symptoms and critical for the associated leg movements. D3 receptors are highly expressed in nucleus accumbens (NAc) of the striatum and the sensory-processing areas of the spinal dorsal horn. In contrast, D1 receptors are strongly expressed throughout the entire striatum and in the ventral horn of the spinal cord. Long-term treatment with D3 receptor full agonists is associated with an upregulation of the D1 receptor subtype, and D3 and D1 receptors can form functional heteromers, in which the D3R controls the D1R function. It is conceivable that the switch from beneficial treatment to augmentation observed in RLS patients after prolonged D3R agonist exposure may be the result of unmasked D1-like receptor actions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akpinar S (1982) Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 39(11):739
Akpinar S (1987) Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 10(1):69–79
Allen RP, Earley CJ (1996) Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19(3):205–213
Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, Lee MR, Nisbet PA (2011) Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 12(5):431–439
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health and International Restless Legs Syndrome Study Group (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4(2):101–119
Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, Garcia-Borreguero D, Kotagal S, Manconi M, Ondo W, Ulfberg J, Winkelman JW, International Restless Legs Syndrome Study Group (2018) Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 41:27–44
Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB (2014) Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. Sleep Med 15(8):860–873
Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L (2005) Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165(11):1286–1292
Barraud Q, Obeid I, Aubert I, Barriere G, Contamin H, McGuire S, Ravenscroft P, Porras G, Tison F, Bezard E, Ghorayeb I (2010) Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate. PLoS One 5(10):e13306
Barrett RJ, Lokhandwala MF (1982) Presynaptic dopamine receptor stimulation and the antihypertensive action of pergolide in experimental neurogenic hypertension. Proc West Pharmacol Soc 25:39–42
Beaulieu JM, Espinoza S, Gainetdinov RR (2015) Dopamine receptors – IUPHAR review 13. Br J Pharmacol 172(1):1–23
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455
Birkmayer W, Hornykiewicz O (1962) The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 203:560–574
Bjorklund A, Skagerberg G (1979) Evidence for a major spinal cord projection from the diencephalic A11 dopamine cell group in the rat using transmitter-specific fluorescent retrograde tracing. Brain Res 177(1):170–175
Bonaventura J, Quiroz C, Cai NS, Rubinstein M, Tanda G, Ferre S (2017) Key role of the dopamine D4 receptor in the modulation of corticostriatal glutamatergic neurotransmission. Sci Adv 3(1):e1601631
Brewer KL, Baran CA, Whitfield BR, Jensen AM, Clemens S (2014) Dopamine D3 receptor dysfunction prevents anti-nociceptive effects of morphine in the spinal cord. Front Neural Circuits 8:62–10
Bruni O, Angriman M, Luchetti A, Ferri R (2015) Leg kicking and rubbing as a highly suggestive sign of pediatric restless legs syndrome. Sleep Med 16(12):1576–1577
Carlsson A, Svennerholm L, Winblad B (1980) Seasonal and circadian monoamine variations in human brains examined post mortem. Acta Psychiatr Scand Suppl 280:75–85
Centonze D, Grande C, Usiello A, Gubellini P, Erbs E, Martin AB, Pisani A, Tognazzi N, Bernardi G, Moratalla R, Borrelli E, Calabresi P (2003) Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 23(15):6245–6254
Chakravarthy S, Balasubramani PP, Mandali A, Jahanshahi M, Moustafa AA (2018) The many facets of dopamine: toward an integrative theory of the role of dopamine in managing the body's energy resources. Physiol Behav 195:128–141
Chenini S, Arnulf I, Monaca CC, Ghorayeb I (2018) French consensus: Pharmacoresistant restless legs syndrome. Rev Neurol (Paris) 174(7–8):522–531
Chipkin RE (2014) Ecopipam treatment of Tourette’s syndrome in subjects 7–17 years, ClinicalTrials.gov. NCT02102698
Chokroverty S (2014) Therapeutic dilemma for restless legs syndrome. N Engl J Med 370(7):667–668
Clemens S, Belin-Rauscent A, Simmers J, Combes D (2012) Opposing modulatory effects of D1- and D2-like receptor activation on a spinal central pattern generator. J Neurophysiol 107:2250–2259
Clemens S, Ghorayeb I (2019) D3 and D1 receptors: the yin and Yang in the treatment of restless legs syndrome with dopaminergics. Adv Pharmacol 84:79–100
Clemens S, Hochman S (2004) Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24(50):11337–11345
Clemens S, Rye D, Hochman S (2006) Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67(1):125–130
Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, Earley CJ (2009) Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 132:2403–2412
Cruz-Trujillo R, Avalos-Fuentes A, Rangel-Barajas C, Paz-Bermudez F, Sierra A, Escartin-Perez E, Aceves J, Erlij D, Floran B (2013) D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat. Neuropharmacology 67:370–378
Didriksen M, Rigas AS, Allen RP, Burchell BJ, Di Angelantonio E, Nielsen MH, Jennum P, Werge T, Erikstrup C, Pedersen OB, Bruun MT, Burgdorf KS, Sorensen E, Ullum H (2017) Prevalence of restless legs syndrome and associated factors in an otherwise healthy population: results from the Danish blood donor study. Sleep Med 36:55–61
Dinkins M-L, Lallemand P, Clemens S (2017) Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor. Sleep Med 40:47–52
Earley CJ, Allen RP, Beard JL, Connor JR (2000) Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 62(5):623–628
Earley CJ, Allen RP, Hening W (2011) Restless legs syndrome and periodic leg movements in sleep. Handb Clin Neurol 99:913–948
Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, Allen R (2014) Altered brain iron homeostasis and dopaminergic function in restless legs syndrome (Willis-Ekbom disease). Sleep Med 15(11):1288–1301
Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas RE, Brasic JR, Ravert HT, Dannals RF, Allen RP (2013) Increased synaptic dopamine in the putamen in restless legs syndrome. Sleep 36(1):51–57
Earley CJ, Uhl GR, Clemens S, Ferre S (2017) Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Med 31:71–77
Ekbom KA (1945) Restless legs syndrome. Acta Med Scand 158:4–122
Ekbom KA (1960) Restless legs syndrome. Neurology 10:868–873
Ferre S (2015) The GPCR heterotetramer: challenging classical pharmacology. Trends Pharmacol Sci 36(3):145–152
Ferre S, Agnati LF, Ciruela F, Lluis C, Woods AS, Fuxe K, Franco R (2007) Neurotransmitter receptor heteromers and their integrative role in ‘local modules’: the striatal spine module. Brain Res Rev 55(1):55–67
Ferri R, Koo BB, Picchietti DL, Fulda S (2017) Periodic leg movements during sleep: phenotype, neurophysiology, and clinical significance. Sleep Med 31:29–38
Ferri R, Zucconi M, Manconi M, Plazzi G, Bruni O, Ferini-Strambi L (2006) New approaches to the study of periodic leg movements during sleep in restless legs syndrome. Sleep 29(6):759–769
Figorilli M, Puligheddu M, Congiu P, Clemens S, Ferri R (2021) In: DelRosso LM, Ferri R (eds) Neurobiology of sleep-related movements. Sleep neurology. Springer
Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74(1):59–69
Fiorentini C, Busi C, Spano P, Missale C (2010) Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Curr Opin Pharmacol 10(1):87–92
Franco R, Ferre S, Agnati L, Torvinen M, Gines S, Hillion J, Casado V, Lledo P, Zoli M, Lluis C, Fuxe K (2000) Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 23(4 Suppl):S50–S59
Fuxe K, Ferre S, Genedani S, Franco R, Agnati LF (2007) Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav 92(1–2):210–217
Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease. Expert Opin Ther Targets 19(3):377–398
Gajendiran M, Seth P, Ganguly DK (1996) Involvement of the presynaptic dopamine D2 receptor in the depression of spinal reflex by apomorphine. Neuroreport 7(2):513–516
Garcia-Borreguero D, Benitez A, Kohnen R, Allen R (2015) Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment. Postgrad Med 127(7):716–725
Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, Manconi M, Montplaisir J, Inoue Y, Allen RP (2013) The long-term treatment of restless legs syndrome/Willis–Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 14(7):675–684
Garcia-Borreguero D, Larrosa O, de la Llave Y, Granizo JJ, Allen R (2004) Correlation between rating scales and sleep laboratory measurements in restless legs syndrome. Sleep Med 5(6):561–565
Garcia-Borreguero D, Silber MH, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21:1–11
Ghorayeb I (2021) In: Monti JM, Pandi-Perumal SR, Murillo-Rodriguez E (eds) Restless legs syndrome. Cannabinoids and sleep – molecular, functional and clinical aspects. Springer
Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE (2014) A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol 37(1):26–30
Gillberg PG, d'Argy R, Aquilonius SM (1988) Autoradiographic distribution of [3H]acetylcholine binding sites in the cervical spinal cord of man and some other species. Neurosci Lett 90(1–2):197–202
Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sanchez-Soto M, Kumar-Barodia S, Naidu YT, Mallol J, Cortes A, Lluis C, Canela EI, Casado V, McCormick PJ, Ferre S (2014) Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer. Mol Pharmacol 86(4):417–429
Han P, Whelan PJ (2009) Modulation of AMPA currents by D(1)-like but not D(2)-like receptors in spinal motoneurons. Neuroscience 158(4):1699–1707
Hening WA (2002) Restless legs syndrome: a sensorimotor disorder of sleep/wake motor regulation. Curr Neurol Neurosci Rep 2(2):186–196
Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH (2004) An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27(3):560–583
Holstege JC, Dijken HV, Buijs RM, Goedkengt H, Gosens T, Bongers CM (1996) Distribution of dopamine immunoreactivity in the rat, cat, and monkey spinal cord. J Comp Neurol 376:631–652
Huang Q, Zhou D, Chase K, Gusella JF, Aronin N, DiFiglia M (1992) Immunohistochemical localization of the D1 dopamine receptor in rat brain reveals its axonal transport, pre- and postsynaptic localization, and prevalence in the basal ganglia, limbic system, and thalamic reticular nucleus. Proc Natl Acad Sci U S A 89(24):11988–11992
Jackisch R, Hotz H, Allgaier C, Hertting G (1994) Presynaptic opioid receptors on dopaminergic nerves in the rabbit caudate nucleus: coupling to pertussis toxin-sensitive G-proteins and interaction with D2 autoreceptors? Naunyn Schmiedebergs Arch Pharmacol 349(3):250–258
Keeler BE, Baran CA, Brewer KL, Clemens S (2012) Increased excitability of spinal pain reflexes and altered frequency-dependent modulation in the dopamine D3-receptor knockout mouse. Exp Neurol 238(2):273–283
Keeler BE, Patel MM, Lallemand P, de Castro Brás LE, Clemens S (2016) Opposing aging-related shift of excitatory dopamine D1and inhibitory D3 receptor protein expression in striatum and spinal cord. J Neurophysiol 115(1):363–369
Khan FH, Ahlberg CD, Chow CA, Shah DR, Koo BB (2017) Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome. J Neurol 264(8):1634–1641
Kondo M, Fujiwara H, Tanaka C (1986) Dopamine release and presynaptic dopaminergic regulation in guinea pig spinal cord. Jpn J Pharmacol 41(1):39–46
Levant B, McCarson KE (2001) D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function. Neurosci Lett 303(1):9–12
Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P, Hokfelt T, Borrelli E, Fisone G (2003) Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci U S A 100(7):4305–4309
Manconi M, Ferri R, Zucconi M, Clemens S, Giarolli L, Bottasini V, Ferini-Strambi L (2011) Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome. Neurology 77(2):110–117
Manconi M, Ferri R, Zucconi M, Oldani A, Fantini ML, Castronovo V, Ferini-Strambi L (2007) First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 8(5):491–497
Marcellino D, Ferre S, Casado V, Cortes A, Le Foll B, Mazzola C, Drago F, Saur O, Stark H, Soriano A, Barnes C, Goldberg SR, Lluis C, Fuxe K, Franco R (2008) Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283(38):26016–26025
Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15(1):17–29
Megelin T, Ghorayeb I (2017) Cannabis for restless legs syndrome: a report of six patients. Sleep Med 36:182–183
Meilak C, Dhawan V, Chaudhuri KR (2004) In: Chaudhuri KR, Odin P, Olanow CW (eds) Clinical features (of RLS). Restless legs syndrome. Taylor & Francis, London, pp 49–56
Montplaisir J, Godbout R, Poirier G, Bedard MA (1986) Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa. Clin Neuropharmacol 9(5):456–463
Montplaisir J, Lorrain D, Godbout R (1991) Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism. Eur Neurol 31(1):41–43
Moreno E, Hoffmann H, Gonzalez-Sepulveda M, Navarro G, Casado V, Cortes A, Mallol J, Vignes M, McCormick PJ, Canela EI, Lluis C, Moratalla R, Ferre S, Ortiz J, Franco R (2011) Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem 286(7):5846–5854
Murray TJ (1967) The restless leg syndrome. Can Med Assoc J 96(24):1571–1574
Navarro M, Fernandez-Ruiz JJ, Rodriguez de Fonseca F, Hernandez ML, Cebeira M, Ramos JA (1992) Modifications of striatal D2 dopaminergic postsynaptic sensitivity during development of morphine tolerance-dependence in mice. Pharmacol Biochem Behav 43(2):603–608
Odin P (2004) In: Chaudhuri KR, Odin P, Olanow CW (eds) Diagnostic criteria. Restless legs syndrome. Taylor & Francis, London, pp 9–20
Odin P, Mrowka M, Shing M (2002) Restless legs syndrome. Eur J Neurol 9(Suppl 3):59–67
Oertel W, Trenkwalder C, Benes H, Ferini-Strambi L, Hogl B, Poewe W, Stiasny-Kolster K, Fichtner A, Schollmayer E, Kohnen R, Garcia-Borreguero D (2011) Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 10(8):710–720
Olianas MC, Dedoni S, Onali P (2012) Potentiation of dopamine D1-like receptor signaling by concomitant activation of delta- and mu-opioid receptors in mouse medial prefrontal cortex. Neurochem Int 61(8):1404–1416
Ondo WG, He Y, Rajasekaran S, Le WD (2000) Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 15(1):154–158
Ondo WG, Olubajo T (2020) Exploratory cross-over, trial of augmented RLS with the dopamine receptor 1/5 antagonist ecopipam D1/D5 antagonist ecopipam for augmented RLS. Int J Neurosci:1–5
Ondo WG, Vuong KD, Jankovic J (2002) Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59(3):421–424
Pearlstein R, Vaz R, Rampe D (2003) Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 46(11):2017–2022
Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini-Strambi L (2007) Restless legs syndrome: prevalence and impact in children and adolescents – the Peds REST study. Pediatrics 120(2):253–266
Picchietti DL, Bruni O, de Weerd A, Durmer JS, Kotagal S, Owens JA, Simakajornboon N, International Restless Legs Syndrome Study Group (2013) Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med 14(12):1253–1259
Price KS, Farley IJ, Hornykiewicz O (1978) Neurochemistry of Parkinson’s disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol 19:293–300
Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583–1590
Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O’Dowd BF, George SR (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 104(2):654–659
Rottach KG, Schaner BM, Kirch MH, Zivotofsky AZ, Teufel LM, Gallwitz T, Messer T (2008) Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 43(1):70–75
Schade R, Vick K, Ott T, Sohr R, Pfister C, Bellach J, Golor G, Lemmer B (1995) Circadian rhythms of dopamine and cholecystokinin in nucleus accumbens and striatum of rats – influence on dopaminergic stimulation. Chronobiol Int 12(2):87–99
Sharples SA, Humphreys JM, Jensen AM, Dhoopar S, Delaloye N, Clemens S, Whelan PJ (2015) Dopaminergic modulation of locomotor network activity in the neonatal mouse spinal cord. J Neurophysiol 113(7):2500–2510
Shin RM, Masuda M, Miura M, Sano H, Shirasawa T, Song WJ, Kobayashi K, Aosaki T (2003) Dopamine D4 receptor-induced postsynaptic inhibition of GABAergic currents in mouse globus pallidus neurons. J Neurosci 23(37):11662–11672
Silvestre JS, Prous J (2005) Research on adverse drug events. I. Muscarinic M-3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27(5):289–304
Skagerberg G, Bjorklund A, Lindvall O, Schmidt RH (1982) Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull 9(1–6):237–244
Skolnick P (2018) The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol 58:143–159
Sowers JR, Vlachakis N (1984) Circadian variation in plasma dopamine levels in man. J Endocrinol Invest 7(4):341–345
Swant J, Stramiello M, Wagner JJ (2008) Postsynaptic dopamine D3 receptor modulation of evoked IPSCs via GABA(A) receptor endocytosis in rat hippocampus. Hippocampus 18(5):492–502
Tamae A, Nakatsuka T, Koga K, Kato G, Furue H, Katafuchi T, Yoshimura M (2005) Direct inhibition of substantia gelatinosa neurones in the spinal cord by activation of dopamine D2-like receptors. J Physiol 568(Pt 1):243–253
Trenkwalder C, Allen R, Hogl B, Clemens S, Patton S, Schormair B, Winkelmann J (2018) Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol 17(11):994–1005
Trenkwalder C, Benes H, Grote L, Garcia-Borreguero D, Hogl B, Hopp M, Bosse B, Oksche A, Reimer K, Winkelmann J, Allen RP, Kohnen R (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12(12):1141–1150
Trenkwalder C, Canelo M, Lang M, Schroeder H, Kelling D, Berkels R, Schollmayer E, Heidbrede T, Benes H (2017) Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med 30:257–265
Trenkwalder C, Paulus W, Walters AS (2005) The restless legs syndrome. Lancet Neurol 4(8):465–475
Trenkwalder C, Winkelmann J, Inoue Y, Paulus W (2015) Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol 11(8):434–445
Verma V, Hasbi A, O'Dowd BF, George SR (2010) Dopamine D1-D2 receptor Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: dual functional regulation by G protein-coupled receptor kinase 2. J Biol Chem 285(45):35092–35103
Vetrugno R, Provini F, Montagna P (2006) Restless legs syndrome and periodic limb movements. Rev Neurol Dis 3(2):61–70
Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C, International Restless Legs Syndrome Study Group (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4(2):121–132
Wanner V, Garcia Malo C, Romero S, Cano-Pumarega I, Garcia-Borreguero D (2019) Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome. Adv Pharmacol 84:187–205
Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A (1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94(1):11–19
Wetter TC, Pollmacher T (1997) Restless legs and periodic leg movements in sleep syndromes. J Neurol 244(4 Suppl 1):S37–S45
Williams AM, Garcia-Borreguero D (2009) Management of restless legs syndrome augmentation. Curr Treat Options Neurol 11(5):327–332
Willis T (1672) De anima brutorum. Davis, R, London
Willis T (1685) Of the diseases of the brain and the genus nervosum. The London practice of Physick. Bassett and Crooke, London
Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, Zee PC, Gronseth GS, Gloss D, Zesiewicz T (2016) Practice guideline summary: treatment of restless legs syndrome in adults: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology. Neurology 87(24):2585–2593
Winkelman JW, Johnston L (2004) Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5(1):9–14
Winkelman JW, Purks J, Wipper B (2021) Baseline and one-year longitudinal data from the National Restless Legs Syndrome Opioid Registry. Sleep 44(2):zsaa183. https://doi.org/10.1093/sleep/zsaa183
Winkelman J, Allen RP, Hogl B, Inoue Y, Oertel W, Salminen AV, Winkelman JW, Trenkwalder C, Sampaio C (2018) Treatment of restless legs syndrome: evidence-based review and implications for clinical practice (revised 2017) (section sign). Mov Disord 33(7):1077–1091
Wu J, Dougherty JJ, Nichols RA (2006) Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors. J Neurochem 98(2):481–494
Yang C, White DP, Winkelman JW (2005) Antidepressants and periodic leg movements of sleep. Biol Psychiatry 58(6):510–514
Yang SN (2000) Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: an essential role of postsynaptic Ca2+. Hippocampus 10(1):57–63
Yepes G, Guitart X, Rea W, Newman AH, Allen RP, Earley CJ, Quiroz C, Ferre S (2017) Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol 82(6):951–960
Zeng C, Wang D, Yang Z, Wang Z, Asico LD, Wilcox CS, Eisner GM, Welch WJ, Felder RA, Jose PA (2004) Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles. Hypertension 43(3):673–679
Zeng C, Wang Z, Li H, Yu P, Zheng S, Wu L, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA (2006) D3 dopamine receptor directly interacts with D1 dopamine receptor in immortalized renal proximal tubule cells. Hypertension 47(3):573–579
Zhu H, Clemens S, Sawchuk M, Hochman S (2007) Expression and distribution of all dopamine receptor subtypes (D1–D5) in the mouse lumbar spinal cord: a real-time polymerase chain reaction and non-autoradiographic in situ hybridization study. Neuroscience 149:885–897
Zhu H, Clemens S, Sawchuk M, Hochman S (2008) Unaltered D1, D2, D4, and D5 dopamine receptor mRNA expression and distribution in the spinal cord of the D3 receptor knockout mouse. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 194(11):957–962
Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, Ferini-Strambi L, Fulda S, Garcia-Borreguero D, Hening WA, Hirshkowitz M, Hogl B, Hornyak M, King M, Montagna P, Parrino L, Plazzi G, Terzano MG (2006) The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 7(2):175–183
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Clemens, S. (2022). D3 Receptors and Restless Legs Syndrome. In: Boileau, I., Collo, G. (eds) Therapeutic Applications of Dopamine D3 Receptor Function. Current Topics in Behavioral Neurosciences, vol 60. Springer, Cham. https://doi.org/10.1007/7854_2022_351
Download citation
DOI: https://doi.org/10.1007/7854_2022_351
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-23057-8
Online ISBN: 978-3-031-23058-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)